

May 14, 2022

| | |
|--|--|
| To The Manager, Listing Department National Stock Exchange of India Limited Plot no. C/1 G Block, Bandra-Kurla Complex, Bandra (East), Mumbai- 400 051 Symbol: BLISSGVS | To The General Manager, Listing Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001 Scrip Code: 506197 |
|--|--|

Subject: Disclosure of Related Party Transactions pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

Pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, please find enclosed herewith the disclosure of Related Party Transactions for the period from October 01, 2021 to March 31, 2022.

Kindly take the same on your record.

Thanking you,

Yours faithfully,

For **Bliss GVS Pharma Limited**


Aditi Bhatt
Company Secretary



Encl: as above

Regd. Office : 102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai - 400 072, INDIA.

TEL. : (+91) (22) 42160000/ 28505387 • FAX. : (+91) (22) 28563930,

Email : info@blissgvs.com • Website : www.blissgvs.com • CIN - L24230MH1984PLC034771

Factory : Plot No. 10, 11 & 12, Survey No. 38/1, Dewan Udyog Nagar, Aliyali Village, Tal. & Dist. Palghar - 401 404.

Tel. (+91) (02525) 252713 • Fax : (+91) (02525) 255257. • Email : factory@blissgvs.com

| | | | | | | | | | | | | | | | | |
|-----|--------------------------|---------------------------------|--|---------------------------------------|--|----------|----------|----------|---|---|---|----------------------|------|---------------------|-----------|--------------------------------------|
| | | | entity or parent | | Committee/Audit Committee/Board | | | | | | | | | | | |
| 10. | Bliss GVS Pharma Limited | Ms. Aditi Bhatt | Key management personnel of entity or parent | Remuneration | As approved by Nomination & Remuneration Committee/Audit Committee/Board | 6.33 | - | - | - | - | - | - | - | - | - | - |
| 11. | Bliss GVS Pharma Limited | Bliss GVS International Pte Ltd | Wholly Owned Subsidiary | Investment in Share Capital | NA | - | 22.58 | 22.58 | - | - | - | Investment in equity | NA | NA | Unsecured | Investment made for business purpose |
| 12. | Bliss GVS Pharma Limited | Bliss GVS International Pte Ltd | Wholly Owned Subsidiary | Interest Income/ Receivable | As Approved by Audit Committee | 151.63 | 372.46 | 507.42 | - | - | - | - | - | - | - | - |
| 13. | Bliss GVS Pharma Limited | Bliss GVS International Pte Ltd | Wholly Owned Subsidiary | Loan Given | As Approved by Audit Committee | 3,660.42 | 4,267.20 | 8,070.93 | - | - | - | Loan | 4.5% | Repayable on Demand | Unsecured | Loan utilised for business |
| 14. | Bliss GVS Pharma Limited | Kremoint Pharma Pvt Ltd | Subsidiary | Labour Charges and purchases of goods | As Approved by Audit Committee | 22.58 | - | - | - | - | - | - | - | - | - | - |
| 15. | Bliss GVS Pharma Limited | Kremoint Pharma Pvt Ltd | Subsidiary | Investment in Share Capital | NA | - | 1,803.00 | 1,803.00 | - | - | - | Investment in equity | NA | NA | Unsecured | Investment made for business purpose |
| 16. | Bliss GVS Pharma Limited | Kremoint Pharma Pvt Ltd | Subsidiary | Paid/Trade Payables | As Approved by Audit Committee | 36.93 | 12.20 | 0.16 | - | - | - | - | - | - | - | - |

| | | | | | | | | | | | | | | | | |
|-----|--------------------------|------------------------------------|-------------------------|------------------------------------|--------------------------------|----------|----------|----------|---|---|---|----------------------|------|---------------------|-----------|--------------------------------------|
| 25. | Bliss GVS Pharma Limited | Asterisk Lifesciences Limited (UK) | Wholly Owned Subsidiary | Investment In Share Capital | As Approved by Audit Committee | - | 0.10 | 0.10 | - | - | - | Investment in equity | NA | NA | Unsecured | Investment made for business purpose |
| 26. | Bliss GVS Pharma Limited | Asterisk Lifesciences Limited (UK) | Wholly Owned Subsidiary | Loan Given | As Approved by Audit Committee | - | 19.86 | 19.80 | - | - | - | Loan | 4.5% | Repayable on Demand | Unsecured | Loan utilised for business |
| 27. | Bliss GVS Pharma Limited | Asterisk Lifesciences Limited (UK) | Wholly Owned Subsidiary | Interest Received/Receivable | As Approved by Audit Committee | 0.44 | 2.06 | 2.50 | - | - | - | - | - | - | - | - |
| 28. | Bliss GVS Pharma Limited | Asterisk Lifesciences Limited (UK) | Wholly Owned Subsidiary | Trade Receivable | As Approved by Audit Committee | - | 17.29 | 16.99 | - | - | - | - | - | - | - | - |
| 29. | Bliss GVS Pharma Limited | Asterisk Lifesciences GH Limited | Step-down Subsidiary | Received/Trade Receivables | As Approved by Audit Committee | 2,620.37 | 4,766.60 | 7,360.55 | - | - | - | - | - | - | - | - |
| 30. | Bliss GVS Pharma Limited | Asterisk Lifesciences GH Limited | Step-down Subsidiary | Reimbursement of Expenses received | As Approved by Audit Committee | 14.80 | - | - | - | - | - | - | - | - | - | - |
| 31. | Bliss GVS Pharma Limited | Asterisk Lifesciences GH Limited | Step-down Subsidiary | Sale of Goods | As Approved by Audit Committee | 5,091.28 | - | - | - | - | - | - | - | - | - | - |
| 32. | Bliss GVS Pharma Limited | Greenlife Bliss Healthcare | Step-down Subsidiary | Trade Receivables | As Approved by Audit Committee | - | 11.23 | 11.46 | - | - | - | - | - | - | - | - |

| | | | | | | | | | | | | | | | |
|--------------------|--------------------------|----------------------------|---|----------|--------------------------------|----------|---|---|---|---|---|---|---|---|---|
| 33. | Bliss GVS Pharma Limited | Bliss GVS Charitable Trust | Enterprise over which KMP exercises significant influence | Donation | As Approved by Audit Committee | 20.00 | - | - | - | - | - | - | - | - | - |
| Total (of Note 6b) | | | | | | 15780.07 | | | | | | | | | |

Note: Foreign balances are reinstated wherever applicable

| |
|---|
| Notes: |
| 1. The details in this format are required to be provided for all transactions undertaken during the reporting period. However, opening and closing balances, including commitments, to be disclosed for existing related party transactions even if there is no new related party transaction during the reporting period. |
| 2. Where a transaction is undertaken between members of the consolidated entity (between the listed entity and its subsidiary or between subsidiaries), it may be reported once. |
| 3. Listed banks shall not be required to provide the disclosures with respect to related party transactions involving loans, inter-corporate deposits, advances or investments made or given by the listed banks. |
| 4. For companies with financial year ending March 31, this information has to be provided for six months ended September 30 and six months ended March 31. Companies with financial years ending in other months, the six months period shall apply accordingly. |
| 5. Each type of related party transaction (for e.g. sale of goods/services, purchase of goods/services or whether it involves a loan, inter-corporate deposit, advance or investment) with a single party shall be disclosed separately and there should be no clubbing or netting of transactions of same type. However, transactions with the same counterparty of the same type may be aggregated for the reporting period. For instance, sale transactions with the same party may be aggregated for the reporting period and purchase transactions may also be disclosed in a similar manner. There should be no netting off for sale and purchase transactions. Similarly, loans advanced to and received from the same counterparty should be disclosed separately, without any netting off. |
| 6. In case of a multi-year related party transaction: a. The aggregate value of such related party transaction as approved by the audit committee shall be disclosed in the column "Value of the related party transaction as approved by the audit committee". b. The value of the related party transaction undertaken in the reporting period shall be reported in the column "Value of related party transaction during the reporting period". |
| 7. "Cost" refers to the cost of borrowed funds for the listed entity. |
| 8. PAN will not be displayed on the website of the Stock Exchange(s). |
| 9. Transactions such as acceptance of fixed deposits by banks/NBFCs, undertaken with related parties, at the terms uniformly applicable /offered to all shareholders/ public shall also be reported. |